TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview

[1]  B. Scallon,et al.  Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Fontana,et al.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.

[3]  David A. Martin,et al.  Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of lewis rats with myelin basic protein , 1995, Experimental Neurology.

[4]  K. Selmaj,et al.  Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I , 1995, Journal of Neuroimmunology.

[5]  S. Endres,et al.  Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids , 1995, European journal of immunology.

[6]  D. Goeddel,et al.  Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice , 1994, Nature.

[7]  B. Scallon,et al.  Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins , 1994, European journal of immunology.

[8]  H. Lassmann,et al.  Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia , 1994, The Journal of experimental medicine.

[9]  J. Antel,et al.  Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor , 1994, Annals of neurology.

[10]  I. Cohen,et al.  Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. , 1994, The Journal of clinical investigation.

[11]  S. Marsters,et al.  Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. , 1994, Journal of immunology.

[12]  William B. Smith,et al.  Dissociation of TNF‐alpha cytotoxic and proinflammatory activities by p55 receptor‐ and p75 receptor‐selective TNF‐alpha mutants. , 1994, The EMBO journal.

[13]  V Balasingam,et al.  Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  M. Cuzner,et al.  Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. , 1993, Cytokine.

[15]  R. Zinkernagel,et al.  Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes , 1993, Nature.

[16]  B. Fleischer,et al.  Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats , 1993, European journal of immunology.

[17]  S. Opal,et al.  Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. , 1992, Lymphokine and cytokine research.

[18]  E. Rieber,et al.  From Antilymphocyte Serum to Therapeutic Monoclonal Antibodies: First Experiences with a Chimeric CD4 Antibody in the Treatment of Autoimmune Disease , 1992, Immunological reviews.

[19]  H. Langstein,et al.  Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. , 1992, Journal of immunology.

[20]  H. Lassmann,et al.  Interferon‐γ potentiates antibody‐mediated demyelination in vivo , 1992 .

[21]  I. Cohen,et al.  T cells in the spinal cord in experimental autoimmune encephalomyelitis are matrix adherent and secrete tumor necrosis factor alpha , 1992, Journal of Neuroimmunology.

[22]  D. Goeddel,et al.  Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Y. Shimamoto,et al.  Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats , 1991, Journal of Neuroimmunology.

[24]  H. Tabuchi,et al.  Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality , 1991, European journal of immunology.

[25]  A. Cross,et al.  Anti—tumor necrosis factor therapy abrogates autoimmune demyelination , 1991, Annals of neurology.

[26]  L. Tartaglia,et al.  The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[28]  C. Brosnan,et al.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.

[29]  S. Gordon,et al.  Regulation of tumor necrosis factor (TNF) release by murine peritoneal macrophages: role of cell stimulation and specific phagocytic plasma membrane receptors , 1991, European journal of immunology.

[30]  R. Ransohoff,et al.  Human astrocytes proliferate in response to tumor necrosis factor alpha , 1990, Journal of Neuroimmunology.

[31]  H. Loetscher,et al.  Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors , 1990, The Journal of experimental medicine.

[32]  R. Clark,et al.  An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis , 1990, The Journal of experimental medicine.

[33]  B. Uitdehaag,et al.  Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages , 1990, The Journal of experimental medicine.

[34]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Merrill,et al.  Tumor necrosis factor identified in multiple sclerosis brain , 1989, The Journal of experimental medicine.

[36]  K. Selmaj,et al.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro , 1988, Annals of neurology.

[37]  C. Brosnan,et al.  Hypothesis: A role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis , 1988, Journal of Neuroimmunology.

[38]  H. Weiner,et al.  A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. , 1987, Journal of immunology.

[39]  V. ter meulen,et al.  Tumor necrosis factor amplifies measles virus-mediated Ia induction on astrocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. ter meulen,et al.  Hyperinducibility of Ia antigen on astrocytes correlates with strain-specific susceptibility to experimental autoimmune encephalomyelitis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Dinarello,et al.  Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. , 1987, Journal of immunology.

[42]  Dr. med. Hans Lassmann.  Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis , 1983, Schriftenreihe Neurologie / Neurology Series.